BSc2118isapotentproteasomeinhibitor.BSc2118showssignificantantimyelomaactivityandmaybeconsideredasapromisingagentincancerdrugdevelopment.BSc2118isalsoapromisingnewcandidateforstroketherapy,whichmayinadditionalleviaterecombinanttissue-plasminogenactivator-inducedbraintoxicity.

MedKooCat#:406453
Name:BSc2118
CAS#:863924-64-5
ChemicalFormula:C28H43N3O7
ExactMass:533.3101
MolecularWeight:533.66
ElementalAnalysis:C,63.02;H,8.12;N,7.87;O,20.99


Synonym:BSc2118;BSc-2118;BSc2118.

IUPAC/ChemicalName:tert-butyl(S)-3-((S)-2-(((benzyloxy)carbonyl)amino)-4-methylpentanamido)-4-(((S)-4-methyl-1-oxopentan-2-yl)amino)-4-oxobutanoate

InChiKey:IWBUYMFIYWDGMJ-VABKMULXSA-N

InChiCode:InChI=1S/C28H43N3O7/c1-18(2)13-21(16-32)29-25(34)23(15-24(33)38-28(5,6)7)30-26(35)22(14-19(3)4)31-27(36)37-17-20-11-9-8-10-12-20/h8-12,16,18-19,21-23H,13-15,17H2,1-7H3,(H,29,34)(H,30,35)(H,31,36)/t21-,22-,23-/m0/s1

SMILESCode:CC(C)C[C@@H](C(N[C@H](C(N[C@H](C=O)CC(C)C)=O)CC(OC(C)(C)C)=O)=O)NC(OCC1=CC=CC=C1)=O


TechnicalData

Appearance:
whitesolidpowder

Purity:
>98%(orrefertotheCertificateofAnalysis)

ShippingCondition:
Shippedunderambienttemperatureasnon-hazardouschemical.ThisproductisstableenoughforafewweeksduringordinaryshippingandtimespentinCustoms.

StorageCondition:
Dry,darkandat0-4Cforshortterm(daystoweeks)or-20Cforlongterm(monthstoyears).

Solubility:
SolubleinDMSO,notinwater

ShelfLife:
>2yearsifstoredproperly

DrugFormulation:
ThisdrugmaybeformulatedinDMSO

StockSolutionStorage:
0-4Cforshortterm(daystoweeks),or-20Cforlongterm(months).

HarmonizedSystemCode:
293490


AdditionalInformation

  
 
 
 


References

1:FuchsO.TargetingofNF-kappaBsignalingpathway,othersignalingpathwaysandepigeneticsintherapyofmultiplemyeloma.CardiovascHematolDisordDrugTargets.2013Mar1;13(1):16-34.Review.PubMedPMID:23534949.

2:DoeppnerTR,Mlynarczuk-BialyI,KuckelkornU,KaltwasserB,HerzJ,HasanMR,HermannDM,BährM.ThenovelproteasomeinhibitorBSc2118protectsagainstcerebralischaemiathroughHIF1Aaccumulationandenhancedangioneurogenesis.Brain.2012Nov;135(Pt11):3282-97.doi:10.1093/brain/aws269.PubMedPMID:23169919.

3:SterzJ,JakobC,KuckelkornU,HeiderU,MiethM,KleebergL,KaiserM,KloetzelPM,SezerO,vonMetzlerI.BSc2118isanovelproteasomeinhibitorwithactivityagainstmultiplemyeloma.EurJHaematol.2010Aug;85(2):99-107.doi:10.1111/j.1600-0609.2010.01450.x.Epub2010Mar31.PubMedPMID:20374272.

4:Młynarczuk-BiałyI,RoeckmannH,KuckelkornU,SchmidtB,UmbreenS,GołabJ,LudwigA,MontagC,WiebuschL,HagemeierC,SchadendorfD,KloetzelPM,SeifertU.Combinedeffectofproteasomeandcalpaininhibitiononcisplatin-resistanthumanmelanomacells.CancerRes.2006Aug1;66(15):7598-605.PubMedPMID:16885359.